THE Australian Register of Therapeutic Goods (ARTG) has listed new or extended uses for four products effective from Jun: Opdivo (nivolumab) sponsored by Bristol-Myers Squibb for Hodgkin lymphoma; Ozurdex (dexamethasone) by Allergan for macular oedema; Pfizer's RA treatment Xeljanz (tofacitinib); and Sanofi-Aventis' Cerezyme (imiglucerase-rch) for enzyme replacement therapy.
Each reference is accompanied with specific conditions and details are at tga.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 06 Jul 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Jul 17
